You just read:

Tolero Pharmaceuticals Announces First Patient Dosed with Investigational Agent TP-1287 in Phase 1 Study in Patients with Advanced Solid Tumors

News provided by

Tolero Pharmaceuticals, Inc.

Jan 10, 2019, 08:00 ET